DE69920930D1 - Methoden und zusammensetzungen für die expression von heterologen genen in leberzellen unter verwendung von vektoren, die von hepadnaviren abgeleitet sind - Google Patents

Methoden und zusammensetzungen für die expression von heterologen genen in leberzellen unter verwendung von vektoren, die von hepadnaviren abgeleitet sind

Info

Publication number
DE69920930D1
DE69920930D1 DE69920930T DE69920930T DE69920930D1 DE 69920930 D1 DE69920930 D1 DE 69920930D1 DE 69920930 T DE69920930 T DE 69920930T DE 69920930 T DE69920930 T DE 69920930T DE 69920930 D1 DE69920930 D1 DE 69920930D1
Authority
DE
Germany
Prior art keywords
methods
hepadnavirus
hepatocytes
expression
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920930T
Other languages
English (en)
Other versions
DE69920930T2 (de
Inventor
Heinz Schaller
Ulrike Protzer
Michael Nassal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69920930D1 publication Critical patent/DE69920930D1/de
Application granted granted Critical
Publication of DE69920930T2 publication Critical patent/DE69920930T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69920930T 1998-08-26 1999-08-26 Methoden und zusammensetzungen für die expression von heterologen genen in leberzellen unter verwendung von vektoren, die von hepadnaviren abgeleitet sind Expired - Lifetime DE69920930T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9817398P 1998-08-26 1998-08-26
US98173P 1998-08-26
PCT/US1999/019452 WO2000012739A1 (en) 1998-08-26 1999-08-26 Methods and compositions for expressing heterologous genes in hepatocytes using hepadnaviral vectors

Publications (2)

Publication Number Publication Date
DE69920930D1 true DE69920930D1 (de) 2004-11-11
DE69920930T2 DE69920930T2 (de) 2005-10-13

Family

ID=22267717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920930T Expired - Lifetime DE69920930T2 (de) 1998-08-26 1999-08-26 Methoden und zusammensetzungen für die expression von heterologen genen in leberzellen unter verwendung von vektoren, die von hepadnaviren abgeleitet sind

Country Status (5)

Country Link
US (1) US20050009185A1 (de)
EP (1) EP1108050B1 (de)
AT (1) ATE278793T1 (de)
DE (1) DE69920930T2 (de)
WO (1) WO2000012739A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137602A0 (en) * 2002-03-26 2002-05-09 Melbourne Health Viral packaging system
US7329485B2 (en) * 2005-10-12 2008-02-12 The Board Of Regents Of The University Of Oklahoma Methods for detecting compounds that interfere with protein aggregation utilizing an in vitro fluorescence-based assay
CN111978414A (zh) * 2020-08-28 2020-11-24 江苏农牧科技职业学院 鸭干扰素γ融合蛋白在制备防治鸭病毒性肝炎药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0933997A4 (de) * 1996-09-06 2000-08-16 Chiron Corp Verfahren und zusammensetzungen für die leberspezifische verabreichung von therapeutischen molekülen unter verwendung rekombinanter aav vektoren
US5981274A (en) * 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors

Also Published As

Publication number Publication date
EP1108050B1 (de) 2004-10-06
EP1108050A1 (de) 2001-06-20
DE69920930T2 (de) 2005-10-13
US20050009185A1 (en) 2005-01-13
WO2000012739A1 (en) 2000-03-09
ATE278793T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
Shen et al. Development of suspension adapted Vero cell culture process technology for production of viral vaccines
Sprinzl et al. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier
Busche et al. Priming of CD8+ T cells against cytomegalovirus-encoded antigens is dominated by cross-presentation
Lenhoff et al. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes
DK1084230T3 (da) Regulering af hæmatopoietisk stamcelledifferentiering ved anvendelse af humane mesenkymstamceller
Du et al. In vivo mouse models for hepatitis B virus infection and their application
CN1657103A (zh) 用于基因转移的病毒包膜载体
CN106591228A (zh) 一种同时抵抗细胞衰老及恶性转化的人多能干细胞的制备方法
JP2002511257A (ja) 目的の遺伝子を発現するための非クローニング技術
Winer et al. Determinants of hepatitis B and delta virus host tropism
Léon et al. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production
Macdonald Development of new cell lines for animal cell biotechnology
CN107937442A (zh) 一种永生化人脂肪间充质干细胞系及其建立方法
Hirsch et al. Replication of duck hepatitis B virus in two differentiated human hepatoma cell lines after transfection with cloned viral DNA
WO2020149395A1 (ja) 栄養障害型表皮水疱症治療薬
DE69920930D1 (de) Methoden und zusammensetzungen für die expression von heterologen genen in leberzellen unter verwendung von vektoren, die von hepadnaviren abgeleitet sind
Hilleman History, precedent, and progress in the development of mammalian cell culture systems for preparing vaccines: safety considerations revisited
Fourel et al. Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: a useful system for antiviral testing
CN102643858B (zh) 一种高效复制的人乙型肝炎病毒重组载体及其应用
Chng et al. Specific adeno‐associated virus serotypes facilitate efficient gene transfer into human and non‐human primate mesenchymal stromal cells
Scherneck et al. Induction of lymphomas by the hamster papovavirus correlates with massive replication of nonrandomly deleted extrachromosomal viral genomes
Min et al. Prolonged gene expression in primary porcine pancreatic cells using an Epstein–Barr virus-based episomal vector
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
Krause et al. Safety of viral DNA in biological products
Harvey et al. The development and characterisation of a SV40 T-antigen positive cell line of human hepatic origin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition